(3-methoxyphenyl)-(3-pyridinyl)methanone | 260417-55-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3-methoxyphenyl)-(3-pyridinyl)methanone
• 英文别名: 3-(3-Methoxybenzoyl)pyridine；(3-methoxyphenyl)-pyridin-3-ylmethanone
• CAS: 260417-55-8
• 化学式: C₁₃H₁₁NO₂
• mdl: MFCD12153278
• 分子量: 213.236
• InChiKey: PQWLVSWJIRPNTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-methoxyphenyl)-(3-pyridinyl)methanone 在 盐酸 、 sodium hydroxide 、 氯化亚砜 、 dimsylsodium 、 四丁基氟化铵 、 氢溴酸 、 对甲苯磺酸 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 34.33h， 生成
  参考文献：
  名称：

  A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

  摘要：

  A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).

  DOI：

  10.1021/jm00010a005
• 作为产物：
  描述：

  3-溴吡啶 在 正丁基锂 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 反应 1.75h， 生成 (3-methoxyphenyl)-(3-pyridinyl)methanone
  参考文献：
  名称：

  A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

  摘要：

  A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).

  DOI：

  10.1021/jm00010a005

文献信息

• 一种含苯基苯并噁唑结构的半夹心钌配合物及其制备方法和应用
  申请人：上海应用技术大学

  公开号：CN112645984B

  公开（公告）日：2022-10-14

  本发明涉及一种含苯基苯并噁唑结构的半夹心钌配合物及其制备方法和应用，该钌配合物具有如下所示结构：其制备方法为：在室温下，将苯基苯并噁唑、[CymRuCl2]2和醋酸钠溶解在甲醇中，将体系升温后，继续反应；反应结束后，静置过滤，减压抽干溶剂，得到的粗产物进行柱层析分离得到红色的含苯基苯并噁唑结构的半夹心钌配合物，并应用于催化烷基吡啶类化合物氧化，制备含氮杂环的酮类化合物。与现有技术相比，本发明制备方法简单绿色、催化氧化反应在温和条件下即可进行、催化剂本身稳定性高、对空气和水均不敏感。
• HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107097A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涵盖了Formula I的化合物，其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还涵盖了一种治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病为类风湿性关节炎或银屑病。该发明还涵盖了通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：——

  公开号：US20020161005A1

  公开（公告）日：2002-10-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 and physiologically acceptable salts thereof.

  本发明涉及新颖化合物和一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受试者施用有效量的化合物1及其生理上可接受的盐。
• Chemokine receptor antagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US06288083B1

  公开（公告）日：2001-09-11

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.

  本发明涉及一种新型化合物及其治疗与异常白细胞招募和/或活化相关的疾病的方法。该方法包括向需要治疗的受体内给予以下结构式所表示的化合物的有效量，以及其生理上可接受的盐。
• Phenyl linked quinolinyl modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US09309222B2

  公开（公告）日：2016-04-12

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及公式I的化合物，其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。本发明还涉及一种治疗或改善综合症、障碍或疾病的方法，其中所述的综合症、障碍或疾病是类风湿性关节炎或银屑病。本发明还涉及一种通过给哺乳动物施用至少一种权利要求1的化合物的治疗有效量来调节RORγt活性的方法。